# A Study of Mirikizumab in Healthy Chinese Participants

> **NCT04137380** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Mirikizumab - IV
- **DRUG:** Mirikizumab - SC
- **DRUG:** Placebo - IV
- **DRUG:** Placebo - SC

## Key facts

- **NCT ID:** NCT04137380
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-04
- **Primary completion:** 2020-12-11
- **Final completion:** 2020-12-11
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04137380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04137380, "A Study of Mirikizumab in Healthy Chinese Participants". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04137380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*